Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Arbutus Biopharma's current 3-Year Share Buyback Ratio was -6.90%.
The historical rank and industry rank for Arbutus Biopharma's 3-Year Share Buyback Ratio or its related term are showing as below:
ABUS'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -56.3 Med: -11.5 Max: 0
Current: -6.9
During the past 13 years, Arbutus Biopharma's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -56.30%. And the median was -11.50%.
ABUS's 3-Year Share Buyback Ratio is ranked better than 60.64% of 1189
companies
in the Biotechnology industry
Industry Median: -11.7
vs ABUS: -6.90
Arbutus Biopharma (NAS:ABUS) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Arbutus Biopharma 3-Year Share Buyback Ratio Related Terms
ABUS vs TBPH, ANNX, SANA: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Arbutus Biopharma's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's 3-Year Share Buyback Ratio falls into.
Arbutus Biopharma 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -6.90 mean?
Arbutus Biopharma (ABUS) has a 3-Year Share Buyback Ratio of -6.90 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Arbutus Biopharma and its competitors. According to the industry distribution chart, Arbutus Biopharma ranks #468 out of 1189 companies in the Biotechnology industry, placing it in the top 39.4%.
Is Arbutus Biopharma's 3-Year Share Buyback Ratio too high?
Arbutus Biopharma's current 3-Year Share Buyback Ratio is -6.90. Based on the distribution chart, Arbutus Biopharma ranks #468 out of 1189 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's 3-Year Share Buyback Ratio compare to TBPH and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #468 out of 1189 companies for 3-Year Share Buyback Ratio. This puts Arbutus Biopharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Arbutus Biopharma and its competitors. Arbutus Biopharma's current 3-Year Share Buyback Ratio is -6.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $50.27, compared to a current price of $4.62 — trading 90.8% below its estimated fair value. The current 3-Year Share Buyback Ratio is -6.90. Arbutus Biopharma's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current 3-Year Share Buyback Ratio is -6.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.62 is trading 90.8% below its estimated GF Value™ of $50.27.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
3-Year Share Buyback Ratio: -6.90
GF Value™: $50.27 vs. price of $4.62 (90.8% below fair value)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score
Get the complete analysis for ABUS
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
